This page lists the SEC filings reported by SUVRETTA CAPITAL MANAGEMENT, LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D | 2024-04-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Benitec Biopharma Inc. | 1,478,490 | 17.4% | EDGAR |
| SC 13G | 2024-04-15 | SUVRETTA CAPITAL MANAGEMENT, LLC | Contineum Therapeutics, Inc. | 1,720,000 | 9.3% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Terns Pharmaceuticals, Inc. | 5,837,126 | 9.5% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Arcellx, Inc. | 2,435,974 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Kezar Life Sciences, Inc. | 7,167,591 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | EyePoint Pharmaceuticals, Inc. | 4,774,389 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Fulcrum Therapeutics, Inc. | 5,518,881 | 8.9% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | MARINUS PHARMACEUTICALS, INC. | 5,463,641 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | SUTRO BIOPHARMA, INC. | 5,778,188 | 9.5% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | 89bio, Inc. | 4,888,434 | 5.2% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Arcutis Biotherapeutics, Inc. | 9,534,837 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Biohaven Ltd. | 4,572,836 | 5.7% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Benitec Biopharma Inc. | 262,843 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | KalVista Pharmaceuticals, Inc. | 2,684,005 | 7.8% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Kura Oncology, Inc. | 7,472,343 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Mereo BioPharma Group plc | 36,854,190 | 5.3% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | PROKIDNEY CORP. | 3,867,847 | 5.8% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Spyre Therapeutics, Inc. | 412,395 | 1.0% | EDGAR |
| SC 13G | 2024-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Cogent Biosciences, Inc. | 5,481,034 | 6.4% | EDGAR |
| SC 13G | 2023-10-30 | SUVRETTA CAPITAL MANAGEMENT, LLC | 89bio, Inc. | 4,808,374 | 6.4% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.